Effect of dimenhydrinate on neural tube development in early chick embryo model

Yıl 2022, Cilt: 47 Sayı: 4, 1507 - 1515, 28.12.2022

Alperen Sarıtaş , Gülan Albaş Kurt , Abdülkadir Bilir , Ozan Turamanlar , Fatih Gürsoy

https://doi.org/10.17826/cumj.1092601

Öz

Purpose: The aim of this study was to investigate the effects of dimenhydrinate on neural tube development in an early chick embryo model.
Materials and Methods: 32 fertile, specific pathogen free eggs were used in the study. All eggs were divided into four groups with 8 eggs in each group. At the 28th hour of the incubation, three different doses of dimenhydrinate (0.7, 1.4, 2.1 mg/kg) were injected into the experimental groups and physiological saline was injected into the control group. At 48th hour of incubation, all embryos were dissected and evaluated histologically under the light microscope.
Results: When the control, low, medium and high dose group embryos were evaluated morphologically, their mean craniocaudal lengths were 8493.73±1342.90 µm, 5743.61±770.3 µm, 5572.62±315.32 µm, 5306.55±1135.99 µm respectively, mean of somite numbers were 15.91±1.62, 15.38±1.19, 15.13±0.83, 10.63±5.15 respectively. Craniocaudal lengths and somite numbers decreased depending on the increase in the dimenhydrinate dose. The incidence of open neural tube increased due to the increase in dimenhydrinate dose.
Conclusion: Neurogenesis and morphological development were negatively affected due to the increase in dose in the groups treated with dimenhydrinate in the early chick embryo model.

Anahtar Kelimeler

Chick embryo, dimenhydrinate, neural tube defect, morphology

Erken dönem civciv embriyo modelinde dimenhidrinatın nöral tüp gelişimi üzerine etkisi

Öz

Amaç: Bu çalışmada dimenhidrinat’ın erken dönem civciv embriyo modelinde nöral tüp gelişimi üzerindeki etkilerinin araştırılması amaçlanmıştır.
Gereç ve Yöntem: Çalışmada 32 fertil, spesifik patojen olmayan yumurta kullanıldı. Tüm yumurtalar her bir grupta 8 adet olacak şekilde dört gruba ayrıldı. İnkübasyonun 28. saatinde deney gruplarına üç farklı dozda (0,7, 1,4, 2,1 mg/kg) dimenhidrinat ve kontrol grubuna serum fizyolojik enjekte edildi. İnkübasyonun 48. saatinde tüm embriyolar diseke edildi ve ışık mikroskobu altında histolojik olarak değerlendirildi.
Bulgular: Kontrol, düşük, orta ve yüksek doz grubu embriyoları morfolojik olarak değerlendirildiğinde, kraniokaudal uzunluk ortalamaları sırasıyla; 8493,73±1342,90 µm, 5743,61±770,3 µm, 5572,62±315,32 µm, 5306,55±1135,99 µm, somit sayıları ortalamaları sırasıyla; 15,91±1,62, 15,38±1,19, 15,13±0,83, 10,63±5,15‘dir. Dimenhidrinat dozundaki artışa bağlı olarak kraniokaudal uzunluklarının ve somit sayılarının azaldığı tespit edildi. Dimenhidrinat doz artışına bağlı olarak nöral tüp açıklığının arttığı belirlendi .
Sonuç: Bu çalışmada, erken dönem civciv embriyo modelinde dimenhidrinat uygulanan gruplarda doz artışına bağlı olarak nörogenezisin ve morfolojik gelişimin olumsuz etkilendiği görüldü.

Anahtar Kelimeler

Civciv embriyosu, dimenhidrinat, nöral tüp defekti, morfoloji

Kaynakça

• 1. Kadir D, Cankara Yuzbasioglu N, Hilal E, Desdicioğlu R, Malas MA. Effects Of Dimenhydrinate And Ondansetron Used In Pregnant Rats On Postnatal Morphometric Development. Trak Universite Tip Fak Derg. 2009; 28
• 2. Einarson A, Maltepe C, Boskovic R, Koren G. Treatment of nausea and vomiting in pregnancy: an updated algorithm. Can Fam Physician. 2007; 53: 2109–11.
• 3. Babaei AH, Foghaha MH. A randomized comparison of vitamin B6 and dimenhydrinate in the treatment of nausea and vomiting in early pregnancy. Iran J Nurs Midwifery Res. 2014; 19: 199–202.
• 4. Eliakim R, Abulafia O, Sherer DM. Hyperemesis gravidarum: a current review. Am J Perinatol. 2000; 17: 207–18.
• 5. Quinla JD, Hill DA. Nausea and vomiting of pregnancy. Am Fam Physician. 2003; 68: 121–8.
• 6. Leathem AM. Safety and efficacy of antiemetics used to treat nausea and vomiting in pregnancy. Clin Pharm. 1986; 5: 660–8.
• 7. Kanamaru Y, Kikukawa A, Miyamoto Y, Hirafuji M. Dimenhydrinate effect on cerebral oxygen status and salivary chromogranin-A during cognitive tasks. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32: 107–15.
• 8. Freyer AM. Drugs in Pregnancy and Lactation 8th Edition: A Reference Guide to Fetal and Neonatal Risk. Obstet Med. 2009; 2: 89.
• 9. Dural EAÖ. Farmakoloji, Ankara, Nobel Tıp Kitabevleri, 2002.
• 10. Gay LN, Carliner PE. The Prevention and Treatment of Motion Sickness I. Seasickness. Science. 1949; 109: 359.
• 11.Strickland BA, Hahn GL. The Effectiveness of Dramamine in the Prevention of Airsickness. Science. 1949; 109: 359–60.
• 12. Halpert AG, Olmstead MC, Beninger RJ. Dimenhydrinate produces a conditioned place preference in rats. Pharmacol Biochem Behav. 2003; 75: 173–9.
• 13. Podgórski R, Stompor - Gorący M, Kubrak T, Podgórska D. Neural tube defects: risk factors and prevention. Eur J Clin Exp Med. 2017; 15: 151–6.
• 14. Avagliano L, Massa V, George TM, Qureshy S, Bulfamante GP, Finnell RH. Overview on neural tube defects: From development to physical characteristics. Birth Defects Res. 2019; 111: 1455–67.
• 15. Thomas JA, Markovac J, Ganong WF. Anencephaly and other neural tube defects. Front Neuroendocrinol. 1994; 15: 197–201.
• 16. Umur A, Yaldiz C, Bursali A, Umur N, Kara B, Barutcuoglu M et al. Evaluation of the Effects of Mobile Phones on the Neural Tube Development of Chick Embryos. Turk Neurosurg. 2013; 23: 742–52.
• 17. Emon ST, Orakdogen M, Uslu S, Somay H. Effects of the popular food additive sodium benzoate on neural tube development in the chicken embryo. Turk Neurosurg. 2015; 25: 294–7.
• 18. Gürcü B, Mete TO, Çöllü F, Aydemi̇r İ, Tuğlu Mİ. The Effects of Lacosamide in the Early Stages of Neural Tube Development in Chick Embryos. Celal Bayar Univ J Sci. 2018; 14: 51–5.
• 19. Hamburger V, Hamilton HL. A series of normal stages in the development of the chick embryo. 1951. Dev Dyn Off Publ Am Assoc Anat 1992; 195: 231–72.
• 20. Lutz BH, Miranda VIA, Silveira MPT, Dal Pizzol T da S, Mengue SS, da Silveira MF et al. Medication Use among Pregnant Women from the 2015 Pelotas (Brazil) Birth Cohort Study. Int J Environ Res Public Health. 2020; 17: E989.
• 21. Gordon CR, Gonen A, Nachum Z, Doweck I, Spitzer O, Shupak A. The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance. J Psychopharmacol Oxf Engl. 2001; 15: 167–72.
• 22. Quaynor H, Ræder JC. Incidence and severity of postoperative nausea and vomiting are similar after metoclopramide 20 mg and ondansetron 8 mg given by the end of laparoscopic cholecystectomies. Acta Anaesthesiol Scand. 2002; 46: 109–13.
• 23. Turner KE, Parlow JL, Avery ND, Tod DA, Day AG. Prophylaxis of postoperative nausea and vomiting with oral, long-acting dimenhydrinate in gynecologic outpatient laparoscopy. Anesth Analg. 2004; 98: 1660–4.
• 24. Hüseyinoğlu Ü, Ülker K. Preoperative Use of 10-mg Metoclopramide and 50-mg Dimenhydrinate in the Prophylaxis of Postoperative Nausea and Vomiting in Elective Caesarean Births: A Prospective Randomized Clinical Study. J Obstet Gynaecol India. 2016; 66: 252–8.
• 25. Ertekin T, Bilir A, Aslan E, Koca B, Turamanlar O, Ertekin A, Albay S. The effect of diclofenac sodium on neural tube development in the early stage of chick embryos. Folia Morphol. 2019; 78: 307–13.
• 26. Bailey J, Knight A, Balcombe J. The future of teratology research is in vitro. Biog Amines. 2005; 19: 97–145.
• 27. Vlastarakos PV, Nikolopoulos TP, Manolopoulos L, Ferekidis E, Kreatsas G. Treating common ear problems in pregnancy: what is safe? Eur Arch Otorhinolaryngol. 2008; 265: 139–45.
• 28. Abell TL, Riely CA. Hyperemesis gravidarum. Gastroenterol Clin North Am. 1992; 21: 835–49.
• 29. Lemay M, Samaan M, St Michel P, Granger L, Pigeon R. Effets immédiats du dimenhydrinate sur la contraction utérine e le rythme cardiaque foetal durant le travail. Can Med Assoc J. 1982; 127: 606–7.
• 30. Czeizel AE, Sárközi A, Wyszynski DF. Protective effect of hyperemesis gravidarum for nonsyndromic oral clefts. Obstet Gynecol. 2003; 101: 737–44.
• 31. Czeizel AE, Vargha P. A case-control study of congenital abnormality and dimenhydrinate usage during pregnancy. Arch Gynecol Obstet. 2005; 271: 113–8.
• 32. Fazliogullari Z, Karabulut AK, Uysal II, Unver Dogan N, Acar H. Investigation of developmental toxicity and teratogenicity of antiemetics on rat embryos cultured in vitro. Anat Histol Embryol. 2013; 42: 239–46.
• 33. Drug Safety Mail 2018-72. https://www.akdae.de/Arzneimittelsicherheit/DSM/Archiv/ 2018-72.html (accessed 19 Dec 2021).
• 34. McColl JD. Dimenhydrinate in Pregnancy. Can Med Assoc J. 1963; 88: 861.
• 35. McColl JD, Robinson S, Globus M. Effect of some therapeutic agents on the rabbit fetus. Toxicol Appl Pharmacol. 1967; 10: 244–52.
• 36. Desdi̇ci̇oğlu K, Cankara N, Evci̇l EH, Desdi̇ci̇oğlu R, Kapucuoğlu N, Malas MA. Gebe Ratlarda Kullanılan Dimenhidrinat ve Ondansetronun Postnatal Dönemdeki Yavru Ratların Organlarında Oluşturacağı Etkilerin Histopatolojik Yönden Araştırılması. J Clin Obstet Gynecol. 2010; 20: 149–54.
• 37. Mellin GW, Katzenstein M. Meclozine and foetal abnormalities. Lancet Lond Engl. 1963; 1: 222–3.
• 38. Gross S, Librach C, Cecutti A. Maternal weight loss associated with hyperemesis gravidarum: a predictor of fetal outcome. Am J Obstet Gynecol. 1989; 160: 906–9.